Inactive Instrument

Ultima Networks plc Share Price London S.E.

Equities

GB0005895098

Pharmaceuticals

End-of-day quote London S.E.
- GBX - Intraday chart for Ultima Networks plc

Financials

Sales 2022 - Sales 2023 1.95K 2.49K 208K Capitalization 2.28M 2.91M 243M
Net income 2022 -1M -1.27M -106M Net income 2023 -1M -1.27M -106M EV / Sales 2022 -
Net cash position 2022 1.92M 2.45M 204M Net cash position 2023 1.03M 1.31M 109M EV / Sales 2023 644 x
P/E ratio 2022
-3.35 x
P/E ratio 2023
-1.63 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 76.96%
More Fundamentals * Assessed data

Latest transcript on Ultima Networks plc

Managers TitleAgeSince
Founder 59 01/14/01
Chief Tech/Sci/R&D Officer - 01/17/01
Members of the board TitleAgeSince
Director/Board Member 46 14/20/14
Founder 59 01/14/01
Chairman - 20/19/20
More insiders
N4 Pharma Plc is a United Kingdom-based pre-clinical stage specialist pharmaceutical company. The Company is engaged in developing Nuvec, which is a novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. It is also engaged in producing LipTide, which is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells. The peptide binds payload and targets specific cells while the lipid allows for efficient endosomal release into the cell. The Company's subsidiary includes N4 Pharma UK Limited and Nanogenics Limited.
More about the company